Infinity Pharmaceuticals, Inc (NASDAQ:INFI) announced that it has appointed José Baselga M.D., Ph.D. and Jeff Berkowitz as independent members of its board of directors. Dr. Baselga, physician-in-chief at Memorial Sloan Kettering Cancer Center, is an accomplished clinician and a thought leader in the PI3K field. Mr. Berkowitz, as the President of Walgreens Boots Alliance Development, GmbH (WAG) in Europe, has a wealth of experience in pharmaceuticals, pharmacy, distribution and market access, pricing and reimbursement. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) shares after opening at $11.07 moved to $11.15 on last trade day and at the end of the day closed at $10.62. Company price to cash ratio in past twelve months was calculated as 2.40. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) showed a negative weekly performance of -11.65%.
MacroGenics, Inc. (NASDAQ:MGNX) a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Jim Karrels, Vice President and Chief Financial Officer, and Eric Risser, Vice President of Business Development, will present at the 13th Annual Needham Healthcare Conference. The presentation will take place Tuesday, April 8, 2014, at 5:00 p.m. Eastern Time in New York. MacroGenics Inc (NASDAQ:MGNX) shares fell -4.47% in last trading session and ended the day on $26.06. MacroGenics Inc (NASDAQ:MGNX) return on equity ratio is recorded as 32.00% and its return on assets is -8.40%.
On Apr 3, Zacks Investment Research upgraded ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to Zacks Rank #1 (Strong Buy). ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares moved down -5.07% in last trading session and was closed at $4.12 while trading in range of $4.00 – $4.42 – ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) year to date (YTD) performance is -5.07%.
Insys Therapeutics, Inc. (Nasdaq:INSY) announced that the Company has completed its previously disclosed three-for-two stock split, effected through a stock dividend. The record date for the stock split was the close of business on March 17, 2014, and share distribution occurred on March 28, 2014. Insys Therapeutics Inc (NASDAQ:INSY) weekly performance is -13.80%. On last trading day company shares ended up $35.16. Insys Therapeutics Inc (NASDAQ:INSY) distance from 50-day simple moving average (SMA50) is -17.00%. Analysts mean target price for the company is $62.00.